If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> A SUPPLEMENT TO NEUROLOGY REVIEWS<br /> Clinical Reviews of JCV and PML<br /> PA R T 2 DECEMBER 2011<br /> Identifying Patients at<br /> Risk for PML<br /> PML in<br /> Immunocompromised<br /> Patient Populations:<br /> Historical Context<br /> PML Risk Factors,<br /> Risk Reduction, and<br /> Improved Outcomes<br /> Emerging Data in<br /> Treatment-Associated<br /> PML<br /> Supported by Biogen Idec<br /> Identifying Patients<br /> at Risk for PML<br /> SUPPLEMENT EDITOR<br /> Mark Gudesblatt, MD<br /> FACULTY<br /> Mark Gudesblatt, MD<br /> Moti L. Chapagain, PhD<br /> John F. Foley, MD<br /> CONTENTS<br /> PML in Immunocompromised<br /> Patient Populations: Historical<br /> Context . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3<br /> Mark Gudesblatt, MD<br /> PML Risk Factors,<br /> Risk Reduction,<br /> a<a title="Biogen 2 Digital Edition page 1" href="http://viewer.zmags.com/publication/360fb0ac?page=1"> A SUPPLEMENT TO NEUROLOGY REVIEWS Clinical Rev</a> <a title="Biogen 2 Digital Edition page 2" href="http://viewer.zmags.com/publication/360fb0ac?page=2"> Identifying Patients at Risk for PML </a> <a title="Biogen 2 Digital Edition page 3" href="http://viewer.zmags.com/publication/360fb0ac?page=3"> PML in Immunocompromised Patient Populations: His</a> <a title="Biogen 2 Digital Edition page 4" href="http://viewer.zmags.com/publication/360fb0ac?page=4"> PML was linked to lymphoproliferative ma- li</a> <a title="Biogen 2 Digital Edition page 5" href="http://viewer.zmags.com/publication/360fb0ac?page=5"> patients increased with disease progression as we</a> <a title="Biogen 2 Digital Edition page 6" href="http://viewer.zmags.com/publication/360fb0ac?page=6"> significantly lower risk of significant disabilit</a> <a title="Biogen 2 Digital Edition page 7" href="http://viewer.zmags.com/publication/360fb0ac?page=7"> lopathy in a patient with idiopathic </a> <a title="Biogen 2 Digital Edition page 8" href="http://viewer.zmags.com/publication/360fb0ac?page=8"> PML Risk Factors, Risk Reduction, and Improved Ou</a> <a title="Biogen 2 Digital Edition page 9" href="http://viewer.zmags.com/publication/360fb0ac?page=9"> PML.6 Although PML and the underlying role of JCV</a> <a title="Biogen 2 Digital Edition page 10" href="http://viewer.zmags.com/publication/360fb0ac?page=10"> periphery relative to active infection in the CNS</a> <a title="Biogen 2 Digital Edition page 11" href="http://viewer.zmags.com/publication/360fb0ac?page=11"> ficity and failed to bind to peripheral cell type</a> <a title="Biogen 2 Digital Edition page 12" href="http://viewer.zmags.com/publication/360fb0ac?page=12"> TABLE 1 Characteristics of AIDS-Associated PML P</a> <a title="Biogen 2 Digital Edition page 13" href="http://viewer.zmags.com/publication/360fb0ac?page=13"> vival in AIDS-associated PML, CD4+ cell count was</a> <a title="Biogen 2 Digital Edition page 14" href="http://viewer.zmags.com/publication/360fb0ac?page=14"> gressive multifocal leukoencephalopathy </a> <a title="Biogen 2 Digital Edition page 15" href="http://viewer.zmags.com/publication/360fb0ac?page=15"> Emerging Data in Treatment- Associated PML John</a> <a title="Biogen 2 Digital Edition page 16" href="http://viewer.zmags.com/publication/360fb0ac?page=16"> In the clinical trials, natalizumab wa</a> <a title="Biogen 2 Digital Edition page 17" href="http://viewer.zmags.com/publication/360fb0ac?page=17"> 0.04 per 1,000 patients in the first year of trea</a> <a title="Biogen 2 Digital Edition page 18" href="http://viewer.zmags.com/publication/360fb0ac?page=18"> The potential for IRIS to serve as a signal </a> <a title="Biogen 2 Digital Edition page 19" href="http://viewer.zmags.com/publication/360fb0ac?page=19"> portant to recognize that patients not initiated </a> <a title="Biogen 2 Digital Edition page 20" href="http://viewer.zmags.com/publication/360fb0ac?page=20"> 20. Foley JF. Progressive escalation of natali- </a>